Vivos Therapeutics
VVOS
29 hedge funds and large institutions have $10.9M invested in Vivos Therapeutics in 2021 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 5 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
101% more capital invested
Capital invested by funds: $5.45M → $10.9M (+$5.49M)
61% more funds holding
Funds holding: 18 → 29 (+11)
0.23% more ownership
Funds ownership: 0.18% → 0.41% (+0.23%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.5M |
| 2 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$1.46M |
| 3 |
BA
Bard Associates
Chicago,
Illinois
|
+$1.4M |
| 4 |
ACM
Archon Capital Management
Seattle,
Washington
|
+$1.4M |
| 5 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$428K |
| 2 |
KJHP
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
-$302K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
-$206K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$105K |
| 5 |
GAM
Griffin Asset Management
New York
|
-$66.5K |
VVOS Hedge Fund Activity: Q2 2021 in Review
29 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q2 2021, worth a combined $10.9M — up 101% from $5.45M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new VVOS positions and 5 closed out — a net gain of 11 holders — while 8 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $2.5M. The largest seller was Millennium Management, cutting an estimated $428K.
- 29 institutional investors held Vivos Therapeutics (VVOS) as of Q2 2021, up from 18 in Q1 2021.
- Funds reported $10.9M of Vivos Therapeutics stock for Q2 2021, up 101% quarter-over-quarter.
- 16 funds opened new Vivos Therapeutics positions in Q2 2021 and 5 closed out, a net change of +11 holders.
- The largest Vivos Therapeutics buyer in Q2 2021 was Vanguard Group, an estimated $2.5M added.
- The largest Vivos Therapeutics seller in Q2 2021 was Millennium Management, an estimated $428K sold.
Based on aggregated 13F filings for Q2 2021.